Cargando…

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Capalbo, Carlo, Scafetta, Giorgia, Filetti, Marco, Marchetti, Paolo, Bartolazzi, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/
https://www.ncbi.nlm.nih.gov/pubmed/30935099
http://dx.doi.org/10.3390/ijms20071607
_version_ 1783413337841729536
author Capalbo, Carlo
Scafetta, Giorgia
Filetti, Marco
Marchetti, Paolo
Bartolazzi, Armando
author_facet Capalbo, Carlo
Scafetta, Giorgia
Filetti, Marco
Marchetti, Paolo
Bartolazzi, Armando
author_sort Capalbo, Carlo
collection PubMed
description Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered. The retrospective immuno-phenotypic analysis performed on the original tumor biopsies allowed for the identification of a specific “galectin signature”, which strongly correlated with tumor responsiveness to anti PD-1 immunotherapy. We observed that the large majority of patients (about 90%) with high galectin-3 tumor expression (score 3+) showed an early and dramatic progression of the disease after three cycles of treatments. In contrast, all patients with negative or low/intermediate expression of galectin-3 in tumor cells showed an early and durable objective response to pembrolizumab, indicating galectin-3 as an interesting predictive marker of tumor responsiveness. The galectin-3 signature, at least in NSCLCs, promises a better selection of patient candidates for immunotherapy, reducing unnecessary treatment exposures and social costs. A large multicenter study is ongoing to validate this finding.
format Online
Article
Text
id pubmed-6479404
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64794042019-04-29 Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs Capalbo, Carlo Scafetta, Giorgia Filetti, Marco Marchetti, Paolo Bartolazzi, Armando Int J Mol Sci Communication Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered. The retrospective immuno-phenotypic analysis performed on the original tumor biopsies allowed for the identification of a specific “galectin signature”, which strongly correlated with tumor responsiveness to anti PD-1 immunotherapy. We observed that the large majority of patients (about 90%) with high galectin-3 tumor expression (score 3+) showed an early and dramatic progression of the disease after three cycles of treatments. In contrast, all patients with negative or low/intermediate expression of galectin-3 in tumor cells showed an early and durable objective response to pembrolizumab, indicating galectin-3 as an interesting predictive marker of tumor responsiveness. The galectin-3 signature, at least in NSCLCs, promises a better selection of patient candidates for immunotherapy, reducing unnecessary treatment exposures and social costs. A large multicenter study is ongoing to validate this finding. MDPI 2019-03-31 /pmc/articles/PMC6479404/ /pubmed/30935099 http://dx.doi.org/10.3390/ijms20071607 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Capalbo, Carlo
Scafetta, Giorgia
Filetti, Marco
Marchetti, Paolo
Bartolazzi, Armando
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title_full Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title_fullStr Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title_full_unstemmed Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title_short Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
title_sort predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in nsclcs
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/
https://www.ncbi.nlm.nih.gov/pubmed/30935099
http://dx.doi.org/10.3390/ijms20071607
work_keys_str_mv AT capalbocarlo predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs
AT scafettagiorgia predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs
AT filettimarco predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs
AT marchettipaolo predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs
AT bartolazziarmando predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs